Novo Nordisk A/S

DelveInsight's 2025 pipeline report reveals a robust obesity therapeutics landscape with over 80 companies developing more than 100 pipeline drugs across various clinical stages.

DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape.

• The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity. • Key players like Novo Nordisk, AstraZeneca, and Viking Therapeutics are developing innovative GLP-1 agonists, including oral formulations, to enhance patient adherence. • Emerging therapies such as VK2735, TERN-601, and ECC5004 are poised to transform the market with improved efficacy and novel mechanisms of action. • GLP-1 agonists are gaining traction beyond diabetes, showing promise in treating obesity and non-alcoholic fatty liver disease (NAFLD), expanding their therapeutic potential.

• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.

• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.

• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.

• Viking Therapeutics' obesity pill demonstrated an average of 6.8% body weight loss over 28 days in early-stage trials, showing promising potential in weight management. • AstraZeneca's weight-loss pill showed a 5.8% weight reduction in diabetic patients, indicating efficacy in a specific population with differential outcomes. • The obesity drug market is projected to reach $130 billion by the end of the decade, intensifying competition among pharmaceutical giants like Eli Lilly and Novo Nordisk. • Pharmaceutical companies are focusing on developing convenient oral medications with minimal side effects to capture a significant share of the expanding obesity treatment market.

• Roche remains confident in its obesity drug candidates despite initial concerns over side effects observed in a small study of CT-388, a weight-loss shot. • The company emphasizes that no patients discontinued treatment due to side effects, which included nausea, vomiting, and diarrhea. • Roche is optimistic about CT-966, an oral weight-loss drug, suggesting it has the potential to be a 'best-in-class' treatment option. • The pharmaceutical giant is actively seeking partnerships in antibody-drug conjugates to diversify its oncology portfolio.